Differing national interpretations of the IVD (in vitro diagnostic) Directive will test manufacturers' ability to comply
This article was originally published in Clinica
The Medical Devices Directive was supposed to create a single European regulatory environment for such products throughout the European Economic Area. But differences in the way individual health authorities have transposed it mean that in practice requirements for manufacturers can vary considerably from country to country. The same will be true of the In Vitro Diagnostics Directive, which has technically just come into force. Maureen Kenny reports.
You may also be interested in...
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.